Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score

Overview of attention for article published in Frontiers in Pharmacology, June 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (55th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 38 Dimensions

Readers on

mendeley: 28 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 7,704 followers.

Igloo-CF / SRC012 - Collaborative research tackling key JLA Cystic Fibrosis Research Priorities https://t.co/w04s6lNdNf https://t.co/IJFduhlhVS https://t.co/7NaDe9PlUF https://t.co/nS7NzSzntZ https://t.co/xDFGxaTYNy #cysticfibrosis @CF_Foundation @cftrus

16 Dec 2023

Reply Repost Favourite

Hot off the press 📢 Comprehensive improvement in GI symptoms (CFAbd-Score) after initiation of elexacaftor/tezacaftor/ivacaftor https://t.co/7pSmXnpF1D

16 Jun 2022

Reply Repost Favourite

New Research: Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score https://t.co/bJ84c1W4Y9 #pharmacology

03 Jun 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.